Stay updated on ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial

Sign up to get notified when there's something new on the ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Revision updated to v3.4.3, replacing v3.4.2.
    Difference
    0.0%
    Check dated 2026-03-12T02:49:30.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Updated study details add a core biopsy requirement for ER IHC and PD testing, and introduce dose escalation with an RP2D plus a palbociclib combination cohort. ARV-471 dosing for Parts A and B is now specified as QD or BID for 28-day cycles, with pharmacokinetic endpoints (AUC) included.
    Difference
    0.8%
    Check dated 2026-02-11T14:15:53.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Added a government funding lapse notice indicating NIH Clinical Center status and updated the system revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T10:25:06.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The page now shows the glossary and new metadata fields (Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data) with revision updated to v3.4.0; older metadata fields and the previous revision v3.3.4 were removed.
    Difference
    0.2%
    Check dated 2026-01-28T06:23:53.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Revision: v3.3.4 was added and Revision: v3.3.3 was removed.
    Difference
    0.0%
    Check dated 2026-01-14T03:19:05.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    The page now includes a consolidated Locations section listing California, Connecticut, Florida, Illinois, Massachusetts, Michigan, Missouri, New Jersey, New York, North Carolina, Tennessee, and Washington, with a new revision tag v3.3.3. The previous state-specific location sections and the HHS Vulnerability Disclosure link have been removed, and the Revision tag changed from v3.3.2.
    Difference
    1%
    Check dated 2025-12-23T20:41:39.000Z thumbnail image

Stay in the know with updates to ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial page.